Molecular Tumor Board

Many of the current HIPO2 projects run in analog manner to established registry trials such as the NCT MASTER program or INFORM, which were established to allow for prospective whole-exome/genome and transcriptome sequencing within a clinical context. In this multidisciplinary initiative molecular data are generated and subsequently evaluated from a clinical perspective in molecular tumor boards with the goal to formulate treatment recommendations for individualized patient care. The molecular tumor board members include translational oncologists, bioinformaticians, molecular biologists, pathologists, and geneticists.

Contact:

NCT-MASTER: This email address is being protected from spambots. You need JavaScript enabled to view it.

INFORM: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

 

 

DKFZ Logo 3zu Research en Black Blue sRGB

4c nctlogo 2009

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.